Swedish device developer Iconovo has received a $350,000 grant from Swedish innovation agency Vinnova for continued development of the company’s ICOone unit-dose disposable dry powder inhaler, the company said.
Iconovo, which is located at the Lund Life Science Incubator recently won a Lund University Innovation Award for an inhaled vaccine project using the ICOone DPI and has signed an agreement with the University of Copenhagen for the use of ICOone in a drug formulation project.
Iconovo CEO Orest Lastow commented, “The grant from Vinnova will help us take a big step toward a commercial product suitable for high-volume manufacturing.”
Lund Life Science Incubator CEO Ebba Fåhraeus said, “Iconovo’s experienced team is trying to solve a global problem which, if successful, will have an impact on world health. Their solution is groundbreaking and it is the kind of company that we want to support at Lund Life Science Incubator. I am pleased that Vinnova chose to provide a grant for this project and look forward to following the developments over the next few years.”
